According to our latest research study on “Leukapheresis Market Forecast to 2028 – COVID-19 Impact and Global Analysis – Product Type, Application, and End User,” the market is projected to reach US$ 133.90 million by 2028 from US$ 74.48 million in 2021; it is estimated to grow at a CAGR of 8.7% from 2021 to 2028.
Leukapheresis is a procedure that has white blood cells (leukocytes) involved in the body’s immune response are segregated from a blood sample. It is a particular form of apheresis in which an element of blood, such as red blood cells or platelets, is obtained while the remaining blood is restored to circulation. Leukapheresis is often used to reduce very high white blood cell (WBC) counts, such as chronic blood cancers like chronic lymphocytic leukemia (CLL). It can also be completed to obtain white blood cells for later transplant, such as to manage abrupt declines in WBC counts throughout cancer chemotherapy. Another use is as a section of a novel form of immunotherapy, termed chimeric antigen receptor (CAR) T-cell therapy, to help fight leukemia, prostate cancer, and other forms of cancers. Leukapheresis can be completed on the person claiming treatment (autologous apheresis) or on a donor for a later transplant (allogeneic apheresis). Currently, leukapheresis is commonly used to treat various diseases, and it is also used for diagnostic purposes as it can increase circulating tumor cells yields.
Download sample PDF Copy https://www.theinsightpartners.com/sample/TIPRE00005515/
Report segments leukapheresis market as follows:
The leukapheresis market is segmented on the basis of product type, application, and end user. Based on product type, the market is bifurcated into leukapheresis devices and leukapheresis disposables. By application, the market is bifurcated into research applications and therapeutic applications. Based on end user, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, blood component providers and blood centers, and hospitals and transfusion centers.
Based on application, the leukapheresis market is bifurcated into research applications and therapeutic applications. In 2021, the research applications segment held a larger share of the market and the same segment is expected to register a higher CAGR during the coming years.
The leukapheresis market majorly consists of the players such as Asahi Kasei Corporation, Fresenius SE & Co. KGaA, Haemonetics Corporation Terumo Corporation, STEMCELL Technologies Inc., HemaCare, Macopharma, AllCells, STEMEXPRESS, and BioIVT amongst others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the leukapheresis market:
- In July-2021, Terumo Blood and Cell Technologies made an announcement of a direct offering for physicians to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient’s bedside. The company has expanded the functionality of Spectra Optia, its industry-leading therapeutic apheresis, cell processing and cell collection platform, with an accessory device, the UVA PIT System.
- In Jan-2020, Fresenius Kabi inaugurated the major expansion of the company’s production site in the Dominican Republic. In Haina, just outside the Dominican Republic’s capital and biggest city, Santo Domingo, the company manufactures apheresis sets. These products are used, for example, to collect blood components such as platelets or plasma. Fresenius Kabi undertook the expansion to meet the rising demand for these high-quality disposables used for critically important donations.